The latest on artificial intelligence transforming medicine

AI and Drug Discovery’s Real Bottleneck: Connecting the Data

A new wave of commentary around AI in biopharma argues that the biggest obstacle is no longer model quality, but the absence of unified, biology-native data infrastructure. The industry may be entering a phase where the winning advantage comes from organizing data as carefully as it trains models.